Skip to main content
. 2018 Sep 29;29(10):1183–1201. doi: 10.1089/hum.2018.137

Table 1.

CD68-ET3-LV CD34+ study design

LV source Sample size Treatment cell dose Post-treatment analyses Post-treatment follow-up duration
CD68-ET3-LV (LTG1434) 4—LV transduced 106 CBC Up to 16 weeks
FVIII activity
VCN
CD68-ET3-LV (pET68-3) 7—Mock
16Untreated
22LV transduced
106 CBC Up to 52 weeks
FVIII activity
VCN
Chemistries (n = 13)

LV, lentiviral vector; CBC, complete blood count; FVIII, factor VIII.